Christoph Kreer

Nov 12, 2023 | nature.com | Philipp Schommers |Dae Sung Kim |Christoph Kreer |Henning Gruell |Elena Knops |Timo Wolf | +10 more

AbstractHuman immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers—persons with HIV-1 who naturally develop broad and potent nAbs—can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens.